Malaria - Pipeline Review, H2 2013 - New Study Released

Global Markets Direct's, 'Malaria - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Malaria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Malaria. Malaria - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Malaria.
* A review of the Malaria products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Malaria pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Full Report Details at
- http://www.fastmr.com/prod/689103_malaria_pipeline_review_h2_2013.aspx?afid=303

Reasons to Get this Report

* Identify and understand important and diverse types of therapeutics under development for Malaria.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Malaria pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned in this Report: Genzyme Corporation, Sanofi-Aventis, AstraZeneca PLC, GlaxoSmithKline plc, Inovio Biomedical Corporation, GenVec, Inc., Novartis AG, Actelion Ltd, Chong Kun Dang Pharmaceutical, Eisai Co., Ltd., Pfizer Inc., Ranbaxy Laboratories Limited, Aduro BioTech, CEL-SCI Corporation, Crucell N.V., Hollis-Eden Pharmaceuticals, Inc., Immtech Pharmaceuticals, Inc., Mymetics Corporation, Patrys Limited, BioCryst Pharmaceuticals, Inc., IPCA Laboratories Limited, Lipoxen PLC, Raptor Pharmaceuticals Corp., Affitech A/S, D-Pharm Ltd., Advinus Therapeutics Pvt. Ltd., Colby Pharmaceutical Company, Bharat Biotech International Limited, Jenrin Discovery, Inc., Mucosis B.V., Statens Serum Institut, Protein Potential, LLC, Amura Holdings Ltd., Anacor Pharmaceuticals, Inc., Telormedix SA, Dilafor AB, Okairos, Ferrer Internacional S.A., Chimerix, Inc., Sanaria Inc., NovaLead Pharma Pvt. Ltd., ImmunoVaccine Technologies Inc., Acetylon Pharmaceuticals, Inc., Etubics Corporation, iBio, Inc., PepTcell Limited, Genocea Biosciences, Inc., Hawaii Biotech, Inc., Georgia Tech Research Corporation, Sigma-Tau Pharmaceuticals, Inc., Selecta Biosciences, Inc., Artificial Cell Technologies, Inc., Pfenex Inc., NeED Pharma s.r.l., VLP Biotech, Inc., Jomaa Pharma GmbH

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Alzheimer's Disease - Pipeline Review, H2 2013
- Influenza - Pipeline Review, H2 2013
- Asthma - Pipeline Review, H2 2013
- Prostate Cancer - Pipeline Review, H2 2013
- Type 2 Diabetes - Pipeline Review, H2 2013